Robert Azelby


Robert Azelby received an average of $6M in total compensation, including $239K in salary, at Juno Therapeutics between 2015 and 2016.

Source: SEC filing on April 21, 2017.

Related executives

We found five more executives who work or worked at Juno Therapeutics.

Hans Bishop

Juno Therapeutics

Chief Executive Officer

Steven Harr

Juno Therapeutics

Chief Financial Officer

Hyam Levitsky

Juno Therapeutics

Chief Scientific Officer

Bernard Cassidy

Juno Therapeutics

General Counsel

Mark Frohlich

Juno Therapeutics

Executive Vice President, Portfolio Strategy

You may also like